Registration for a live webinar on 'Rare disease clinical trials: challenges and best practices' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Talk outline
- Cardiovascular disease: Risk factors
- Aging is the number 1 risk factor for CVD
- Aging changes in cardiac cycle
- Intrinsic cardiac aging
- Clinical importance of HFpEF in aging population
- Characteristics of murine cardiac aging
- Other parameters of cardiac aging
- Assays for cardiac function in mouse model
- Part II: Molecular mechanisms for cardiac aging
- mTOR signaling
- mTORC1 and protein homeostasis
- Altered nutrient and growth signaling
- Macromolecule damage and mitochondrial ROS
- Mitochondrial polymerase gamma mutation
- Dysregulated cardiac metabolism
- Extracellular matrix (ECM) in aged hearts
- Changes in factors that regulate ECM
- ECM remodeling regulation by MMPs
- Impaired calcium homeostasis in aged hearts
- Upregulated Angiotensin II signaling in aged hearts
- miRNA and cardiac aging
- Sirtuins and cardiac aging
- Cell senescence, renewal and stem cell function
- Molecular mechanisms for cardiac aging
- Part III: Recent advances in potential interventions
- Calorie restriction (CR)
- CR and rapamycin inhibit TORC1 signaling
- Rapamycin
- Rapamycin and cardiac proteome remodeling
- Mitochondrial interventions (e.g. SS-31)
- Diastolic function, MPI & Hypertrophy in old mice
- Inhibition of Angiotensin signaling
- Others: miRNA and cardiac stem cell therapies
- Growth differentiation factor: GDF-11
- Potential interventions for cardiac aging
- Part IV: Future perspectives
Topics Covered
- Cardiac aging in human and animal models
- Molecular mechanisms for cardiac aging
- Recent advances on potential interventions for cardiac aging
- Future perspectives of cardiac aging interventions
Talk Citation
Rabinovitch, P. and Chiao, Y.A. (2016, May 31). Cardiac aging [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 30, 2024, from https://doi.org/10.69645/MWJW6162.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Peter Rabinovitch, Grant/Research Support (Principal Investigator): NIH grant support only
- Ms. Ying Ann Chiao, Grant/Research Support (Principal Investigator): NIH/NIA K99 grant support
Other Talks in the Series: Aging
Transcript
Please wait while the transcript is being prepared...
0:00
Hello.
My name is Ying Ann Chiao.
and
I'm Peter Rabinovitch.
We'll be presenting
on the topic cardiac aging.
0:09
Cardiovascular diseases are
the leading cause of death
for the elderly population.
In this lecture, we will discuss
the impact of aging on the heart.
We'll begin by an
overview of cardiac aging
in human and mammalian models.
We'll then discuss the involvements
of multiple molecular mechanisms
in the pathogenesis of cardiac
aging and the recent advances
in the development of
interventions to delay or treat
cardiac aging as well as
perspectives on the future
of the cardiac aging field.
0:41
Multiple factors have
been shown to increase
the risk of cardiovascular disease.
The Heart, Lung, and Blood Institute
of National Institutes of Health
has listed risk factors
for cardiovascular disease,
including high blood cholesterol and
triglyceride, high blood pressure,
diabetes, overweight, smoking,
lack of physical activity,
unhealthy diet, and stress.
The Center for Disease
Control and Prevention
also lists blood cholesterol,
hypertension, diabetes,
and family history as risk factors.
Most of the research
assays on prevention
of cardiovascular diseases
have focused on the development
of interventions that target these
traditional cardiovascular risk
factors but have
ignored a major risk
factor for cardiovascular
diseases aging.
1:34
This slide shows the prevalence of
cardiovascular disease in adults 20
years or older of age by age
and sex from the national health
and nutrition examination
survey 2009 to 2012
from heart disease
and stroke statistic.
This data includes coronary
heart disease, heart
failure, stroke, and hypertension.
As you can see, the patterns
of cardiovascular diseases
increase with age dramatically.
The prevalence of
cardiovascular disease
is close to 70% for Americans
60 to 70 years of age
and is over 80% for Americans
over 80 years of age.
In addition to the
increased prevalence
of cardiovascular
diseases, aging also
leads to deterioration
of the structure
and function of the heart
in individuals without overt
cardiovascular disease.